Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urothelial Cancer 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Neoplasms 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Chordoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Malignancies 1Advanced Rare Malignant Solid Neoplasm 1

Interventions

Gemcitabine 3Cisplatin 3Carboplatin 3pembrolizumab 2erdafitinib 2vinflunine 1tremelimumab 1enfortumab vedotin 1durvalumab 1atezolizumab 1Tiragolumab 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urothelial Cancer × Tiragolumab × Clear all
NCT05645692 2026-04-29

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Hoffmann-La Roche

Phase 2 Active not recruiting
204 enrolled
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡